Search results for "Standard"

showing 10 items of 3299 documents

Can life be standardized? Current challenges in biological standardization

2021

The concept of standard strongly evokes machines, industries, electric or mechanical devices, vehicles, or furniture. Indeed, our technological civilization would not be possible – at least in the terms it is structured today – without universal, reliable components, whose acknowledged use results in competitive costs, robustness and interchangeability. For example, an Ikea screw can be used in a wide set of structurally dissimilar furniture and an app can be run on many different smartphones. The very concept of standardization is linked to the industrial revolution and mass production of goods through assembly lines. The question we will try to answer in the present paper is the extent to…

0301 basic medicineMultidisciplinaryStandardizationComputer scienceContext-dependencyModularityInterchangeabilityPromiscuity03 medical and health sciences030104 developmental biology0302 clinical medicineHistory and Philosophy of ScienceRisk analysis (engineering)Robustness (computer science)RealmNoise030217 neurology & neurosurgeryMechanical devicesSynthetic biologyMètode Revistade difusió de lainvestigació
researchProduct

A multicentric study to evaluate the use of relative retention times in targeted proteomics.

2016

Despite the maturity reached by targeted proteomic strategies, reliable and standardized protocols are urgently needed to enhance reproducibility among different laboratories and analytical platforms, facilitating a more widespread use in biomedical research. To achieve this goal, the use of dimensionless relative retention times (iRT), defined on the basis of peptide standard retention times (RT), has lately emerged as a powerful tool. The robustness, reproducibility and utility of this strategy were examined for the first time in a multicentric setting, involving 28 laboratories that included 24 of the Spanish network of proteomics laboratories (ProteoRed-ISCIII). According to the results…

0301 basic medicineMultiple reaction monitoringProteomicsBiomedical ResearchComputer scienceBiophysicsLiquid chromatographyContext (language use)BioinformaticsBiochemistry03 medical and health sciencesInter-laboratory validationTargeted proteomicsObserver VariationReproducibilityResearchReproducibility of ResultsAnalytical scienceReference StandardsStandardizationReproducibilityCell and molecular biologyTargeted proteomics030104 developmental biologyBiological significanceBiochemical engineeringRetention timeChromatography LiquidJournal of proteomics
researchProduct

Melanoma-Nevus Discrimination Based on Image Statistics in Few Spectral Channels

2016

The purpose of this paper is to offer a method for discrimination of cutaneous melanoma from benign nevus, founded on analysis of skin lesion image. At the core of method is calculation of mean and standard deviation of pixel optical density values for a few narrow spectral bands. Calculated values are compared with discriminating thresholds derived from a set of images of benign nevi and melanomas with known diagnosis. Classification is done applying weighted majority rule to results of thresholding. Verification against the available multispectral images of 32 melanomas and 94 benign nevi has shown that the method using three spectral bands provided zero false negative and four false posi…

0301 basic medicineNevi and melanomasContextual image classificationImage classificationmelanoma detection.Multispectral imageSpectral bandsbiomedical optical imagingmedicine.disease01 natural sciencesThresholdingStandard deviation010104 statistics & probability03 medical and health sciences030104 developmental biologyCutaneous melanomaStatisticsmultispectral imagingmedicineNevus0101 mathematicsElectrical and Electronic EngineeringMathematicsElektronika ir Elektrotechnika
researchProduct

Toxicity reduction of ochratoxin A by lactic acid bacteria.

2017

Abstract Ochratoxin A (OTA) is a mycotoxin produced by the metabolism of fungus belonging to the genus Aspergillus and Penicillium. In this paper we report, the capacity of different cultures of lactic acid bacteria (LAB) to degrade OTA present in MRS broth at both pH 3.5 and 6.5. A study of OTA reduction during gastrointestinal digestion carried out with the LAB was also performed. Taking into account the two reduction mechanisms of OTA studied in this work as the enzymatic one and the adsorption on the cell wall, as well as at pH 3.5 and 6.5 the reduction values of OTA were in a range of 30–99%, being the strains with greater reduction (97% and 95%) Lb. rhamnosus CECT 278T and Lb. plantar…

0301 basic medicineOchratoxin APhenylalanine030106 microbiologyPhenylalanineFood ContaminationToxicologyMass Spectrometry03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyCell WallLactobacillalesHumansFood scienceMycotoxinAspergillusbiologyfood and beverages04 agricultural and veterinary sciencesGeneral MedicineMetabolismReference Standardsbiology.organism_classification040401 food scienceOchratoxinsLactic acidCulture MediaGastrointestinal TractchemistryPenicilliumInactivation MetabolicAdsorptionBacteriaFood ScienceChromatography LiquidFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct

Genetically elevated gamma-glutamyltransferase and Alzheimer's disease

2018

Observational epidemiological evidence supports a linear and independent association between serum gamma-glutamyltransferase (GGT) concentrations and the risk of Alzheimer's disease (AD). However, the causality of this association has not been previously investigated. We sought to assess the causal nature of this association using a Mendelian randomization (MR) approach. Using inverse-variance weighted MR analysis, we assessed the association between GGT and AD using summary statistics for single nucleotide polymorphism (SNP)-AD associations obtained from the International Genomics of Alzheimer's Project of 17,008 individuals with AD and 37,154 controls. We used 26 SNPs significantly associ…

0301 basic medicineOncologyAgingentsyymitDisease030204 cardiovascular system & hematologyAlzheimerin tautiBiochemistryGWAS genome-wide association studiestransferaasit0302 clinical medicineEndocrinologyEpidemiologyMedicineNHGRI National Human Genome Research InstituteGamma-glutamyltransferasebiologyMR Mendelian randomizationGenetic Pleiotropyta3142SNP single nucleotide polymorphismAlzheimer's disease3. Good healthEuropeAD Alzheimer's diseasegeneettiset tekijätmedicine.medical_specialtySingle-nucleotide polymorphismGRS genetic risk scoreta3111Polymorphism Single NucleotideArticle03 medical and health sciencesAlzheimer DiseaseInternal medicineMendelian randomizationGeneticsMendelian randomizationSNPHumansMolecular Biologybusiness.industryGGT gamma-glutamyltransferaseIGAP International Genomics of Alzheimer's ProjectGenetic VariationGamma-glutamyltransferaseCell BiologyOdds ratioMendelian Randomization AnalysisConfidence intervalCI confidence intervalOR odds ratio030104 developmental biologyCase-Control Studiesbiology.proteinbusinessSD standard deviationGenome-Wide Association StudyExperimental Gerontology
researchProduct

Non-Radiation Based Early Pain Relief Treatment Options for Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: A Systematic Review

2020

Introduction: Cancer induced bone pain (CIBP) is frequent in patients with non-small cell lung cancer (NSCLC). Radiation therapy continues to be the gold standard for treatment of painful bone metastases, however only a limited number of metastases can be irradiated. We evaluated non-radiation based early CIBP relief options in NSCLC through a systematic review. Methods: Systematic review including all prospective articles published between 01-1994 and 06-2020 on Pubmed, Cochrane Library and ClinicalTrials.gov database. Inclusion: nonradiation based trials evaluating CIBP early pain relief options (initially defined as pain score evaluated within two weeks, because of no randomized trials, …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPain reliefcancer induced bone painCochrane Librarylcsh:RC254-282DISEASEpain relieflaw.inventionPALLIATIVE RADIOTHERAPY03 medical and health sciences0302 clinical medicineRandomized controlled trialSDG 3 - Good Health and Well-beingbone metastasessystematic reviewlawQUALITY-OF-LIFEInternal medicinemedicineLung cancerBone painIBANDRONATEbisphosphonatesnon-small cell lung cancerDENOSUMABbusiness.industryGold standardCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensEFFICACYRadiation therapy1ST-LINE TREATMENT030104 developmental biologyMETASTASESOncology030220 oncology & carcinogenesisZOLEDRONIC ACIDmedicine.symptombusinessFrontiers in Oncology
researchProduct

Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

2018

Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisPoly (ADP-Ribose) Polymerase-1Placebos0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsPromoter Regions GeneticDNA Modification MethylasesAged 80 and overStandard treatmentNuclear ProteinsMiddle AgedNeoplastic Cells CirculatingImmunohistochemistryhumanitiesEditorialOncology030220 oncology & carcinogenesisFemaleNon small cellAdultmedicine.medical_specialtyMEDLINEAggressive disease03 medical and health sciencesText miningDouble-Blind MethodInternal medicinemedicineBiomarkers TumorTemozolomideHumansLung cancerneoplasmsAntineoplastic Agents AlkylatingAgedbusiness.industryTumor Suppressor ProteinsDNA Methylationmedicine.diseaseSmall Cell Lung Carcinomarespiratory tract diseases030104 developmental biologyDNA Repair EnzymesBenzimidazolesPersonalized medicinebusiness
researchProduct

Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives.

2019

Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high morbidity and mortality; indeed the majority of OSCC has been lately identified in the advanced clinical stage (i.e., III or IV). Moreover, after primary treatment, recurrences and/or metastases are found in more than half of the patients (80% of cases within the first 2 years) and the 5-year survival rate is still lower than 50%, resulting in a serious issue for public health. Currently, histological investigation represents the “gold stan…

0301 basic medicineOncologySalivamedicine.medical_specialtyPhysiologyReviewlcsh:Physiology03 medical and health sciencesliquid biopsy salivary biomarkers circulating tumor DNA extracellular vesicles microRNAs early diagnosis prognosis oral squamous cell carcinoma0302 clinical medicinesalivary biomarkersInternal medicinePhysiology (medical)microRNAMedicineLiquid biopsyStage (cooking)Survival ratecirculating tumor DNAlcsh:QP1-981liquid biopsybusiness.industryCancerGold standard (test)medicine.diseasemicroRNAsoral squamous cell carcinomastomatognathic diseases030104 developmental biology030220 oncology & carcinogenesisBiomarker (medicine)prognosisbusinessextracellular vesiclesearly diagnosisFrontiers in physiology
researchProduct

International consensus guidelines for scoring the histopathological growth patterns of liver metastasis

2017

BACKGROUND: Liver metastases present with distinct histopathological growth patterns (HGPs), including the desmoplastic, pushing and replacement HGPs and two rarer HGPs. The HGPs are defined owing to the distinct interface between the cancer cells and the adjacent normal liver parenchyma that is present in each pattern and can be scored from standard haematoxylin-and-eosin-stained (H&E) tissue sections. The current study provides consensus guidelines for scoring these HGPs.METHODS: Guidelines for defining the HGPs were established by a large international team. To assess the validity of these guidelines, 12 independent observers scored a set of 159 liver metastases and interobserver var…

0301 basic medicineOncologycongenital hereditary and neonatal diseases and abnormalitiesCancer Researchmedicine.medical_specialtyPathologyIntraclass correlationmedicine.medical_treatmentcolorectal cancerGuidelineMetastasisangiogenesis03 medical and health sciencesbreast cancer0302 clinical medicineSDG 3 - Good Health and Well-beingInternal medicineJournal ArticlemedicineHumansNeoplasm Metastasisprognostic factorintegumentary systembusiness.industryLiver Neoplasmsnutritional and metabolic diseasesvessel co-optionGold standard (test)medicine.diseaseliver metastasis030104 developmental biologyTissue sectionsPractice GuidelineOncology030220 oncology & carcinogenesisCancer cellCohortBiomarker (medicine)Hepatectomytumour microenvironmentbusinessBritish Journal of Cancer
researchProduct

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

2018

Abstract Background Standard treatment options for patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) are associated with limited efficacy and some toxicity. Recently, immunotherapy with antibodies that inhibit the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) interaction has emerged as a new treatment option. This manuscript reviews early-phase and late-phase trials of immunotherapy in advanced GC/GEJC. Methods Searches for studies of immunotherapy in GC/GEJC were performed using PubMed, ClinicalTrials.gov, and abstract databases for select annual congresses. Findings were interpreted based on expert opinion. Results Monotherapy with anti–PD-1/PD-L1 …

0301 basic medicineOncologymedicine.medical_specialtyDurvalumabPhases of clinical researchPembrolizumabAvelumab03 medical and health sciences0302 clinical medicineAtezolizumabStomach NeoplasmsInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingNeoplasm Metastasisbusiness.industryStandard treatmentGeneral MedicineImmune checkpoint030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyNivolumabbusinessmedicine.drugCancer treatment reviews
researchProduct